In this issue:
Interventions targeting mood for improving inflammatory biomarkers in IBD
Risk factors for malignancy and serious infections in IBD
Maternal/neonatal outcomes in vedolizumab-and ustekinumab-exposed pregnancies
Different maintenance ustekinumab intervals in IBD
Adherence to endoscopic surveillance guidelines in IBD
Coffee/caffeine reduces UC risk
Tofacitinib for recapturing response in UC following dose reduction/interruption
Sustained long-term effectiveness of thiopurines for IBD
Psychodynamic psychotherapy for adolescents/young adults with IBD
Tofacitinib vs. prednisolone for inducing remission in moderately active UC
Please login below to download this issue (PDF)